Want to see CSBR full AI Analyst Report?
Top Page
Champions Oncology
(NASDAQ:CSBR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.00
▲(0.40% Upside)
Action:Reiterated
Date:09/12/26
Overall score is pulled down primarily by weak TTM financial performance (revenue contraction, cash burn, and higher leverage). Technicals remain mixed-to-weak with the stock below key longer-term moving averages. These negatives are partly offset by a strong, upbeat earnings call highlighting recent quarter margin expansion, positive adjusted EBITDA, and continued operational progress, but execution and cash/lumpiness risks remain material.
Positive Factors
Margin and EBITDA Expansion
Improving gross margin and a sustained run of positive adjusted EBITDA indicate better operating leverage in the core services model. If maintained, this combination can support reinvestment, reduce dependence on external funding, and improve earnings quality over the next several quarters.
Negative Factors
TTM Revenue Contraction and Volatile Profitability
The sharp TTM revenue decline and repeated movement between profit and loss reduce confidence in earnings durability. Such volatility makes planning and resource allocation harder, and leaves future results more dependent on successful execution and sustained customer project demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin and EBITDA Expansion
Improving gross margin and a sustained run of positive adjusted EBITDA indicate better operating leverage in the core services model. If maintained, this combination can support reinvestment, reduce dependence on external funding, and improve earnings quality over the next several quarters.
Read all positive factors
Champions Oncology Key Performance Indicators (KPIs)
Any
Revenue By Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This can indicate strategic focus and potential areas for expansion or risk.
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This can indicate strategic focus and potential areas for expansion or risk.
Data provided by:
The Fly
The FlyChampions Oncology (CSBR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$68.20M
Dividend YieldN/A
Average Volume (3M)10.95K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth6.65%
EPS Growth-136.61%
CountryUS
Employees214
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding13,918,569
10 Day Avg. Volume15,714
30 Day Avg. Volume10,951
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.93
Price to Sales (P/S)1.39
P/FCF Ratio-16.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)$65.26M
Champions Oncology Business Overview & Revenue Model
Company Description
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the hea...
How the Company Makes Money
Champions Oncology primarily makes money by delivering fee-for-service research and development support to biopharmaceutical companies and other research organizations developing cancer therapeutics. Revenue is generated from contracted services t...
Champions Oncology Earnings Call Summary
Earnings Call Date:Sep 10, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Dec 15, 2026
Earnings Call Sentiment Positive
The call was strongly positive overall. Management reported approximately 9% revenue growth, significant gross and oncology services margin expansion, the fifth consecutive quarter of positive adjusted EBITDA, stronger data licensing revenue, healthy services demand, and continued Corellia progress. The main cautions were the remaining GAAP net loss, cash usage, lumpy timing of data licensing revenue, higher sales and marketing expense from planned investment, and uncertainty around the timing of a Corellia funding or licensing outcome.Positive Updates
Revenue Growth
First-quarter revenue was $15.2 million, up approximately 9% from $14 million in the first quarter of fiscal 2026.
Negative Updates
GAAP Net Loss Remained
Despite improved operating results, the company reported a GAAP net loss of approximately $426,000 for the quarter.
Read all updates
Q1-2027 Updates
Positive
Negative
Revenue Growth
First-quarter revenue was $15.2 million, up approximately 9% from $14 million in the first quarter of fiscal 2026.
Read all positive updates
Company Guidance
For fiscal '27, management said it has 3 more quarters to prove out the progress and will keep reporting against it in the same way each time, with a focus on continuing to grow revenue while expanding profitability, maintaining expense discipline, and converting revenue growth into improved profitability; expected conversion percentages remain strong, data license revenue will remain lumpy, and pipeline continues to be robust. Management said it was not going to put a date on any Corellia outcome, but if successful in securing outside funding or a licensing partnership, the investment currently flowing into that business would be redeployed toward other growth initiatives, particularly data and to the bottom line.Champions Oncology Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
34
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.66M | 59.42M | 56.94M | 50.16M | 53.87M | 49.11M |
| Gross Profit | 29.91M | 28.52M | 28.55M | 20.75M | 24.34M | 25.48M |
| EBITDA | 447.00K | 448.00K | 6.27M | -5.44M | -3.02M | 2.21M |
| Net Income | -1.14M | -1.18M | 4.70M | -7.28M | -5.33M | 548.00K |
Balance Sheet | ||||||
| Total Assets | 33.29M | 26.99M | 32.34M | 26.13M | 34.31M | 35.38M |
| Cash, Cash Equivalents and Short-Term Investments | 4.36M | 4.87M | 9.79M | 2.62M | 10.12M | 9.01M |
| Total Debt | 10.97M | 4.51M | 6.11M | 7.43M | 8.60M | 9.47M |
| Total Liabilities | 28.83M | 22.92M | 28.57M | 28.04M | 29.68M | 26.28M |
| Stockholders Equity | 3.89M | 3.94M | 3.77M | -1.90M | 4.64M | 9.10M |
Cash Flow | ||||||
| Free Cash Flow | -6.14M | -5.04M | 7.00M | -6.97M | 1.08M | 4.11M |
| Operating Cash Flow | -5.56M | -4.47M | 7.39M | -6.14M | 3.96M | 6.50M |
| Investing Cash Flow | -549.00K | -540.00K | -389.00K | -836.00K | -2.87M | -2.38M |
| Financing Cash Flow | 146.00K | 99.00K | 170.00K | -527.00K | 11.00K | 207.00K |
Champions Oncology Technical Analysis
Negative
4.98
Price Trends
5.25
Negative
5.64
Negative
5.99
Negative
Market Momentum
-0.05
Negative
42.83
Neutral
34.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 4.98 is below the 20-day moving average (MA) of 5.06, below the 50-day MA of 5.25, and below the 200-day MA of 5.99, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 42.83 is Neutral, neither overbought nor oversold. The STOCH value of 34.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.
Champions Oncology Risk Analysis
Champions Oncology disclosed 30 risk factors in its most recent earnings report. Champions Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Champions Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $120.75M | -3.47 | -21.01% | ― | -13.15% | 21.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $96.47M | -2.00 | -103.08% | ― | -6.96% | 32.77% | |
48 Neutral | $108.01M | -2.47 | -38.80% | ― | -100.00% | -392.92% | |
46 Neutral | $68.20M | -62.41 | -27.88% | ― | 6.65% | -136.61% | |
45 Neutral | $87.13M | -2.73 | 1020.21% | ― | ― | 2.05% | |
45 Neutral | $15.60M | -0.67 | -456.35% | ― | ― | 9.68% |
* Healthcare Sector Average
CSBR
Champions Oncology
4.93
-1.45
-22.73%
ONCY
Oncolytics Biotech
0.66
-0.75
-52.98%
CRDF
Cardiff Oncology
1.20
-0.88
-42.31%
MXCT
MaxCyte
1.16
-0.34
-22.67%
BDTX
Black Diamond Therapeutics
1.83
-1.90
-50.94%
LTRN
Lantern Pharma
1.09
-3.45
-75.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.